key: cord-0712223-5wjry2cz
authors: Bertrand, Dominique; Hanoy, Mélanie; Edet, Stéphane; Lemée, Veronique; Hamzaoui, Mouad; Laurent, Charlotte; Ludivine, Lebourg; Etienne, Isabelle; Lemoine, Mathilde; Nezam, Dorian; Candon, Sophie; Plantier, Jean-Christophe; Le Roy, Frank; Guerrot, Dominique
title: Antibody response to SARS-CoV-2 messenger RNA BNT162b2 vaccine in kidney transplant recipients and in-centre and satellite centre haemodialysis patients
date: 2021-06-11
journal: Clin Kidney J
DOI: 10.1093/ckj/sfab100
sha: be83929d2f8b53c4ddede5d477cbed071f4310cc
doc_id: 712223
cord_uid: 5wjry2cz

nan

Pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been particularly deleterious in patients with end-stage renal disease (ESRD) [1, 2] . Emerging data report a low rate of immunization after two doses of messenger RNA (mRNA) in kidney transplantation [3] , but higher rates in dialysis patients [4] . We report here the humoural response to two injections of mRNA BNT162b2 vaccine in subpopulations of ESRD patients.

Between 15 January and 30 April 2021, 505 kidney transplant recipients (KTRs) and 62 in-centre haemodialysis patients (HDPs) followed in Rouen University Hospital and 59 HDPs from our medical satellite facility received two injections of Pfizer SARS-CoV-2 mRNA BNT162b2 vaccine 21 days apart. Among them, 235 KTRs and all HDPs were examined for humoural immune response after a mean time of 34.6 days [interquartile range (IQR) 22.5-62.2] following the second dose. No patient included in this cohort had a previous history of SARS-CoV-2 infection. The anti-SARS-CoV-2 post-vaccination antibody response against the spike protein was assessed using the ARCHITECT immunoglobulin G (IgG) II Quant test (Abbott Laboratories, Abbott Park, IL, USA), with titres of >50 arbitrary units per milliliter (AU/mL) being considered as positive. This retrospective study was submitted for approval by the Rouen Centre Institutional Review Board (CERNI No. E2021-37).

Among the 235 KTRs (mean age 60. Table 1 . KTRs under belatacept therapy had a lower rate of seroconversion (4.2%).

Among the 62 in-centre HDPs (mean age 73.3 6 13.8 years, sex 31 males/31 females), 57 (91.9%) developed antibodies. The median titre in responders was 1554 AU/mL (IQR 307-2586) ( Figure 1 ). One patient, with negative serology, developed severe COVID-19 4 days after the second injection. Among the 59 HDPs Our results confirm the low rate of immunization in KTRs after two doses of mRNA vaccine, as recently reported by others. Boyarsky et al. [3] reported a rate of immunization of 54% in 658 solid organ recipients. The immune response is largely influenced by immunosuppression regimen and is particularly low with the usual association of tacrolimus and mycophenolate mofetil [3] and with belatacept [5] . However, the occurrence of severe infections after vaccination in KTR, reported in our study and by others [6] is worrying. Our results also confirm [4] the high degree of seroconversion in HDPs, although with lower titres of antibodies compared with the general population. A strong correlation between neutralizing antibody levels and protection from symptomatic COVID-19 after vaccination is now reported [7] . We report for the first time, reassuring data for HDPs in a medical satellite facility. These patients are younger and have fewer comorbidities than in-centre HDPs.

In conclusion, the mRNA BNT162b2 vaccine seems efficient in HDPs, particularly in HDPs in medical satellite facilities, indicating that vaccination should be highly recommended in these patients, and overall in waitlisted patients for kidney transplantation. In contrast, the low seroconversion rate observed in KTRs is worrying. In seronegative patients, a third dose of vaccine might trigger a humoural response. However, in patients failing to generate any response, should immunizing household members and close contacts be the priority? 

Is COVID-19 infection more severe in kidney transplant recipients?

Results from the ERA-EDTA Registry indicate a high mortality due to COVID-19 in dialysis patients and kidney transplant recipients across Europe

Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients

Haemodialysis patients show a highly diminished antibody response after COVID-19 mRNA vaccination compared to healthy controls

Poor anti-SARS-CoV-2 humoral and T-cell responses after 2 Injections of mRNA vaccine in kidney transplant recipients treated with belatacept

Occurrence of severe COVID-19 in vaccinated transplant patients

Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection

The authors declare that the results presented in this article have not been published previously in whole or part. None of the authors declare any conflicts of interest.